Breaking
In Japan, executives of a pharmaceutical company involved in development receives "replicon (self-amplifying mRNA)" vaccine Regarding the newly adopted replicon vaccine in the regular vaccinations for COVID-19 this fall, Joseph Payne, CEO of Arcturus Therapeutics, one of the companies involved in its development, stated in an interview with Kyodo News on the 8th, "It is safer because it requires a smaller dose compared to conventional vaccines that use messenger RNA (mRNA) as the genetic material.'"The company is developing vaccines and medicines using mRNA and a system called replicon, in which mRNA replicates within the body. The replicon vaccine "Kostaive," developed in collaboration with Japan's Meiji Seika Pharma, is the first practical product for Arcturus. 47news.jp/11597063.html
In Japan, executives of a pharmaceutical company involved in development receives "replicon (self-amplifying mRNA)" vaccine Regarding the newly adopted replicon vaccine in the regular vaccinations for COVID-19 this fall, Joseph Payne, CEO of Arcturus Therapeutics, one of the companies involved in its development, stated in an interview with Kyodo News on the 8th, "It is safer because it requires a smaller dose compared to conventional vaccines that use messenger RNA (mRNA) as the genetic material.'"The company is developing vaccines and medicines using mRNA and a system called replicon, in which mRNA replicates within the body. The replicon vaccine "Kostaive," developed in collaboration with Japan's Meiji Seika Pharma, is the first practical product for Arcturus. 47news.jp/11597063.html
357
Views